Maitland Pharma Corp announce launch of its new drug PEPTERON

ORLANDO, FLORIDA – 04-14-2020 ( — (PRDistribution) – Maitland Pharma Corp announces the launch later this month of its new drug PEPTERON, licensed from the Irish company Kosama Scientific Ltd. PEPTERON is currently registered in the USA as a cobra venom preparation based homeopathic drug for the temporary relief of symptoms of colds and flu, including rhinitis, fever, sore throat and headache.

Based on the scientific research and our efforts to date, it is our opinion that PEPTERON could play a potential role in the COVID-19 pandemic subject to the efficacy shown by purpose designed clinical studies. Cobra venom preparations have shown excellent safety profile in clinical studies for multiple conditions in the past but has not been tested for preventive or therapeutic efficacy against COVID-19. Cobra venom preparations have demonstrated a range of activities to include broad spectrum antiviral efficacy against multiple viruses including data in corona virus-infected animals. Animal data revealed the alleviation of the acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection as well as the potential ability to suppress the cytokine storm observed in severely ill COVID-19 patients. Maitland Pharma Corp is working with academic partners to initiate clinical studies to test PEPTERON in individuals at high risk of SARS-CoV2 virusexposure and patients with COVID-19 symptoms.



Maitland Pharma Corp is in the process of contracting multiple distributors under Maitland’s label, and also under distributors’ own label. Our contracted distributors are required to obtain approval on press releases from Maitland Pharma Corp in advance of circulation and we take no responsibility for the accuracy of statements and claims made in unauthorised releases. We are aware of one such release, dated April 10th, 2020, and wish to advise the public that the Naja venom preparation that we sell under the name of PEPTERON is  a drug that does require registration with relevant authorities in each country and cannot be sold without such approval. Furthermore, any claims for use of this product as antiviral treatment or prophylaxis for COVID-19 will require additional clinical trials and regulatory approval in advance of such claims being made. In the face of the worldwide pandemic with multiple patients dying every day, we feel that providing evidence-based information is a matter of social responsibility.



MAITLAND PHARMA CORP is a biotech company with a mission to provide innovative, flexible and cost-effective approaches to the development, formulation, and production of sterile drugs and sterile products via its affiliated FDA registered 503b pharmacy, Maitland Labs of Central Florida, and to deliver specialized clinical development service via its partner of 20 years, Immunoclin Limited, a UK healthcare company.


[email protected]


[email protected]

Media Contacts:

Company Name: Maitland Pharma Corp
Full Name: Paul Reid
Phone: 7542241242
Email Address: Send Email

For the original news story, please visit